Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $75.51M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Fujifilm JPY 1.26T 57.74B Mar/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Merck USD 27.73B 786M Jun/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Perrigo USD 1.05B 57.2M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026
Zoetis USD 2.06B 8M Jun/2026